专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010031056A3 METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY 审中-公开
标题翻译：调节IRE1，SRC和ABL活性的方法和组合物
公开(公告)号：WO2010031056A3
公开(公告)日：2010-08-05
申请号：PCT/US2009056993
申请日：2009-09-15
申请人： UNIV CALIFORNIA , WALTER PETER , KORENNYKH ALEXEI , SHOKAT KEVAN M , ZHANG CHAO , FINER-MORE JANET , STROUD ROBERT , EGEA PASCAL , KOROSTELEV ANDREI , DAR ARVIN
发明人： WALTER PETER , KORENNYKH ALEXEI , SHOKAT KEVAN M , ZHANG CHAO , FINER-MORE JANET , STROUD ROBERT , EGEA PASCAL , KOROSTELEV ANDREI , DAR ARVIN
IPC分类号： C07D403/14 , A61K31/497 , A61P25/28 , C07D401/12 , C07D401/14 , C07D403/12
CPC分类号： C07D403/12 , A61K31/4155 , A61K31/497 , C07D401/14 , C07D403/14
摘要： Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
摘要翻译：本文公开的是用于调节Ire1，Src或Ab1的组合物，用于鉴定测试化合物中调节活性的方法，以及用于治疗由Ire1，Src或Abl的活性或不活动引起的疾病的方法。

2. 发明申请

WO2006068760A2 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES 审中-公开
标题翻译：抗炎药吡唑并嘧啶类
公开(公告)号：WO2006068760A2
公开(公告)日：2006-06-29
申请号：PCT/US2005042524
申请日：2005-11-21
申请人： UNIV CALIFORNIA , BIOSEEK INC , SHOKAT KEVAN M , SEPETOV NIKOLAI , ZHANG CHAO , GSCHWEND HIENZ , KUNKEL ERIC J
发明人： SEPETOV NIKOLAI , ZHANG CHAO , GSCHWEND HIENZ , KUNKEL ERIC J
IPC分类号： C07D487/04 , A61K31/505 , A61P29/00 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition.
摘要翻译：本发明提供了用于治疗其中炎症参与疾病进展或疾病或病症症状的表现的疾病和病症的抗炎化合物。

3. 发明申请

WO2005007085A2 PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF 审中-公开
标题翻译：吡咯并吡啶衍生物及其使用方法
公开(公告)号：WO2005007085A2
公开(公告)日：2005-01-27
申请号：PCT/US2004019782
申请日：2004-06-21
申请人： UNIV CALIFORNIA , TANAKA MASAHIRO , ZHANG CHAO , SHOKAT KEVAN M , BURLINGAME ALMA L , HANSEN KIRK , BATEMAN RAYNARD L , DIMAGNO STEPHEN G
发明人： TANAKA MASAHIRO , ZHANG CHAO , SHOKAT KEVAN M , BURLINGAME ALMA L , HANSEN KIRK , BATEMAN RAYNARD L , DIMAGNO STEPHEN G
IPC分类号： A61K20060101 , A61K31/519 , A61K31/5377 , A61P35/00 , C07D487/02 , C07D487/04 , A61K
CPC分类号： C07D487/04
摘要： This invention generally relates to pyrazolo pyrimidine derivatives useful as, inter alia, inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. More specifically, the invention relates to pyrazolo pyrimidine derivatives, including derivatives and analogs of SDR inhibitors, pharmaceutical compositions containing derivatives and analogs of SDR inhibitors, methods of making derivatives and analogs of SDR inhibitors and methods of use thereof.
摘要翻译：本发明一般涉及用作特别是NAD（P）（H）依赖性氧化还原酶的短链脱氢酶/还原酶（SDR）家族的抑制剂的吡唑并嘧啶衍生物。更具体地，本发明涉及吡唑并嘧啶衍生物，包括SDR抑制剂的衍生物和类似物，含有SDR抑制剂的衍生物和类似物的药物组合物，制备SDR抑制剂的衍生物和类似物的方法及其使用方法。

4. 发明申请

WO2007038613A3 SELECTIVE SERINE/THREONINE KINASE INHIBITORS 审中-公开
标题翻译：选择性丝氨酸/螺旋激酶抑制剂
公开(公告)号：WO2007038613A3
公开(公告)日：2007-11-22
申请号：PCT/US2006037699
申请日：2006-09-26
申请人： UNIV CALIFORNIA , TAUNTON JACK , COHEN MICHAEL , SHOKAT KEVAN , ZHANG CHAO
发明人： TAUNTON JACK , COHEN MICHAEL , SHOKAT KEVAN , ZHANG CHAO
IPC分类号： G01N33/00 , G01N33/53
CPC分类号： C07D487/04 , C07D239/42 , C07D403/06 , C07D487/14 , C07D519/00
摘要： Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase. Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase. Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.
摘要翻译：在ATP结合位点内具有一个或多个半胱氨酸残基的蛋白激酶的抑制通过使本身或细胞或受试者中的激酶与抑制有效量的具有由两个或更多个的杂环核心结构组成的化合物接触来实现含有至少一个氮环原子的稠合环，以及能够与激酶的ATP结合位点内的半胱氨酸残基反应的亲电取代基。优选的化合物包括具有这样的亲电子取代基的某些吡咯并嘧啶和羟吲哚，以及任选的能够与位于激酶的关守位置的苏氨酸或更小残基相互作用的芳族或杂芳族取代基。缺乏这种半胱氨酸残基的激酶可以被改造或修饰，使得它们能够被这样的化合物抑制，通过用半胱氨酸残基替换ATP结合位点内的缬氨酸或其它氨基酸残基。

5. 发明申请

WO2005000197A3 SELECTIVE SERINE/THREONINE KINASE INHIBITORS 审中-公开
标题翻译：选择性丝氨酸/螺旋激酶抑制剂
公开(公告)号：WO2005000197A3
公开(公告)日：2005-09-01
申请号：PCT/US2004011297
申请日：2004-04-12
申请人： UNIV CALIFORNIA , TAUNTON JACK , COHEN MICHAEL , SHOKAT KEVAN , ZHANG CHAO
发明人： TAUNTON JACK , COHEN MICHAEL , SHOKAT KEVAN , ZHANG CHAO
IPC分类号： A61K20060101 , C07D487/04
CPC分类号： C07D487/04
摘要： Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase. Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase. Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.
摘要翻译：在ATP结合位点内具有一个或多个半胱氨酸残基的蛋白激酶的抑制通过使本身或细胞或受试者中的激酶与抑制有效量的具有由两个或更多个的杂环核心结构组成的化合物接触来实现含有至少一个氮环原子的稠合环，以及能够与激酶的ATP结合位点内的半胱氨酸残基反应的亲电取代基。优选的化合物包括具有这样的亲电子取代基的某些吡咯并嘧啶和羟吲哚，以及任选的能够与位于激酶的关守位置的苏氨酸或更小残基相互作用的芳族或杂芳族取代基。缺乏这种半胱氨酸残基的激酶可以被改造或修饰，使得它们能够被这样的化合物抑制，通过用半胱氨酸残基替换ATP结合位点内的缬氨酸或其它氨基酸残基。

6. 发明申请

WO2011127865A3 METHOD, APPARATUS, AND SYSTEM FOR PROCESSING MEMORY DUMP 审中-公开
标题翻译：用于处理存储器的方法，装置和系统
公开(公告)号：WO2011127865A3
公开(公告)日：2012-04-19
申请号：PCT/CN2011074721
申请日：2011-05-26
申请人： HUAWEI TECH CO LTD , LI JUN , ZHANG CHAO
发明人： LI JUN , ZHANG CHAO
IPC分类号： G06F12/06 , G06F3/06
CPC分类号： G06F11/0778 , G06F11/3037
摘要： A method, an apparatus, and a system for processing memory dump are provided. The method includes: invoking a first processing unit group to process the first part of the memory dump processing of each memory block; invoking each processing unit group other than the first processing unit group to respectively process the subsequent processing part after accomplishing the processing of the first part, in order to write the memory blocks into a storage device. The technical scheme provided in the present invention can enable processing each part of each memory block in a pipelining way, avoid instantaneous peak flow of disk I/O transmission, and improve the memory dump performance.
摘要翻译：提供了一种用于处理存储器转储的方法，装置和系统。该方法包括：调用第一处理单元组以处理每个存储器块的存储器转储处理的第一部分; 调用除第一处理单元组之外的每个处理单元组，以在完成第一部分的处理之后分别处理后续处理部分，以便将存储块写入存储装置。本发明提供的技术方案可以以流水线方式处理每个存储块的每个部分，避免磁盘I / O传输的瞬时峰值流动，并提高存储器转储性能。

7. 发明申请

WO2011079133A3 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR 审中-公开
标题翻译：化合物及其调节方法及其适应症
公开(公告)号：WO2011079133A3
公开(公告)日：2011-11-17
申请号：PCT/US2010061601
申请日：2010-12-21
申请人： PLEXXIKON INC , IBRAHIM PRABHA N , WU GUOXIAN , LIN JACK , SPEVAK WAYNE , CHO HANNA , EWING TODD , ZHANG CHAO
发明人： IBRAHIM PRABHA N , WU GUOXIAN , LIN JACK , SPEVAK WAYNE , CHO HANNA , EWING TODD , ZHANG CHAO
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： C07D471/04 , A61K31/437 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/519 , C07D519/00
摘要： Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on each of B-Raf, B-Raf V600E and c-Raf-1 protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including melanoma, glioma, glioblastoma, pilocytic astrocytoma, liver cancer, biliary tract cancer, cholangiocarcinoma, colorectal cancer, lung cancer, bladder cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, kidney cancer, ovarian cancer, adrenocortical cancer, prostate cancer, gastrointestinal stromal tumors, medullary thyroid cancer, tumor angiogenesis, acute myeloid leukemia, chronic myelomonocytic leukemia, childhood acute lymphoblastic leukemia, plasma cell leukemia, and multiple myeloma.
摘要翻译：其化合物及其盐，其制剂，其缀合物，其衍生物，其形式及用途。在某些方面和实施方案中，所述的化合物或其盐，其制剂，其缀合物，其衍生物，其形式在B-Raf，B-Raf V600E和c-Raf-1蛋白激酶中的每一个上都是活性的。在某些方面和实施方案中，所述化合物在抑制Ras突变细胞系的增殖中是有活性的。还描述了其用于治疗疾病和病症的方法，包括黑素瘤，神经胶质瘤，成胶质细胞瘤，纤维细胞性星形细胞瘤，肝癌，胆道癌，胆管癌，结肠直肠癌，肺癌，膀胱癌，胆囊癌，乳腺癌，胰腺癌，甲状腺癌，肾癌，卵巢癌，肾上腺皮质癌，前列腺癌，胃肠道间质瘤，甲状腺髓样癌，肿瘤血管生成，急性骨髓性白血病，慢性骨髓单核细胞白血病，儿童急性淋巴细胞性白血病，浆细胞白血病和多发性骨髓瘤。

8. 发明申请

WO2010129467A8 COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR 审中-公开
标题翻译：化合物和方法，用于抑制RENIN及其适应症
公开(公告)号：WO2010129467A8
公开(公告)日：2010-12-16
申请号：PCT/US2010033385
申请日：2010-05-03
申请人： PLEXXIKON INC , WU GUOXIAN , IBRAHIM PRABHA N , ZHOU YONG , MAMO SHUMEYE , GILLETTE SAMUEL J , ZHU YONG-LIANG , LIU JINYU , ZHANG CHAO , ZHANG KAM , ARTIS DEAN R
发明人： WU GUOXIAN , IBRAHIM PRABHA N , ZHOU YONG , MAMO SHUMEYE , GILLETTE SAMUEL J , ZHU YONG-LIANG , LIU JINYU , ZHANG CHAO , ZHANG KAM , ARTIS DEAN R
IPC分类号： C07D215/06 , A61K31/47 , A61P9/12 , C07D215/227 , C07D401/06 , C07D407/06 , C07D409/06 , C07D413/06 , C07D417/06
CPC分类号： C07D215/06 , C07D215/227 , C07D401/06 , C07D407/06 , C07D409/06 , C07D413/06 , C07D417/06
摘要： Compounds active as inhibitors of renin (e.g., compounds of Formula I) are described, as well as methods of using such compounds to treat diseases and conditions associated with the renin-angiotensin system. Formula (I)
摘要翻译：描述了作为肾素抑制剂活性的化合物（例如式I的化合物），以及使用这些化合物治疗与肾素 - 血管紧张素系统相关的疾病和病症的方法。式（I）

9. 发明申请

WO2008063888A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR 审中-公开
标题翻译：调节C-FMS和/或C-KIT活性的化合物及其用途
公开(公告)号：WO2008063888A2
公开(公告)日：2008-05-29
申请号：PCT/US2007083910
申请日：2007-11-07
申请人： PLEXXIKON INC , ZHANG CHAO , ZHANG JIAZHONG , IBRAHIM PRABHA N , ARTIS DEAN R , BREMER RYAN , WU GUOXIAN , ZHU HONGYAO , NESPI MARIKA
发明人： ZHANG CHAO , ZHANG JIAZHONG , IBRAHIM PRABHA N , ARTIS DEAN R , BREMER RYAN , WU GUOXIAN , ZHU HONGYAO , NESPI MARIKA
IPC分类号： C07D471/04 , A61K31/437
CPC分类号： C07D471/04 , A61K31/444 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06
摘要： Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
摘要翻译：本文提供了对受体蛋白酪氨酸激酶c-kit和/或c-fms具有活性的化合物。本文还提供了用于治疗c-kit介导的疾病或病症和/或c-fms介导的疾病或病症的组合物，及其使用方法。

10. 发明申请

WO2006026655A8 SYSTEMS AND METHODS TO AVOID DEADLOCK AND GUARANTEE MIRROR CONSISTENCY DURING ONLINE MIRROR SYNCHRONIZATION AND VERIFICATION 审中-公开
标题翻译：在线镜像同步和验证期间避免死锁和保证镜像一致性的系统和方法
公开(公告)号：WO2006026655A8
公开(公告)日：2008-02-21
申请号：PCT/US2005030943
申请日：2005-08-31
申请人： EMC CORP , ZHANG CHAO , FREY ROBERT TOWER
发明人： ZHANG CHAO , FREY ROBERT TOWER
IPC分类号： G06F12/10
CPC分类号： H04L67/1097 , G06F11/2071 , G06F11/2082 , H04L67/1095
摘要： Systems and methods can provide mirrored virtual targets and online synchronization and verification of the targets while avoiding deadlock, inconsistencies between members of the target, and false verification failures. A lock within the storage switch can limit the number of outstanding commands for a physical target to one during synchronization and verification operations. In one embodiment; a lock can be implemented as one or more resource tables maintaining an indication of the number of transfer ready signals available from physical targets. During typical write operations, deadlock can be avoided by determining whether each physical target for the mirrored operation can issue a transfer ready signal prior to issuing a command to the physical target. When a synchronization or verification operation begins, the maximum available number of transfer ready signals for each target can be decremented to one in order to limit the total number of outstanding commands for each target to one.
摘要翻译：系统和方法可以提供镜像虚拟目标和在线同步和目标验证，同时避免死锁，目标成员之间的不一致以及虚假的验证失败。存储交换机内的锁可以在同步和验证操作期间将物理目标的未完成命令的数量限制为一个。在一个实施例中; 可以将锁定实现为一个或多个资源表，其保持从物理目标可用的传送就绪信号的数量的指示。在典型的写入操作期间，通过确定镜像操作的每个物理目标是否可以在向物理目标发出命令之前发出传输就绪信号，可以避免死锁。当同步或验证操作开始时，每个目标的传送就绪信号的最大可用数量可以减少到1，以便将每个目标的未完成命令的总数限制为1。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式